International Research Journal of Innovations in Engineering and Technology (IRJIET)
ISSN (online): 2581-3048
Volume 9, Special Issue INSPIRE'25, pp 116-120, April-2025
https://doi.org/10.47001/IRJIET/2025.INSPIRE19
International Conference on Sustainable Practices and Innovations in Research and Engineering (INSPIRE'25)

The Rise and Fall of IBM Watson in Healthcare: Lessons for Sustainable AI Innovations

[1]Dr.S.Sathya, [2]Pooja S, [3]Paruvathani G, [4]Sharmi J

[1]Associate Professor, Department of AI&DS, GRT Institute of Engineering and Technology, Tiruttani, Tamilnadu, India
[2,3,4]UG Student, Department of AI&DS, GRT Institute of Engineering and Technology, Tiruttani, Tamilnadu, India

***Abstract* - IBM has been a cornerstone of technological innovation for over a century, pioneering advancements in computing, artificial intelligence, and enterprise solutions. Despite its early dominance, IBM struggled to maintain its competitive edge in the evolving tech landscape, facing setbacks in personal computing, software, and AI adoption. This case study examines IBM's historical rise, the challenges that led to its decline, and its strategic attempts at revival, with a particular focus on its AI-driven oncology tool, Watson. IBM Watson for Oncology was introduced as a groundbreaking AI solution for cancer diagnosis and treatment. However, its reliance on hypothetical data rather than real-world patient cases, lack of transparency in decision-making, and inability to integrate seamlessly with medical practices led to skepticism among healthcare professionals. This case study analyzes Watson's failure as a cautionary tale for AI in healthcare and explores IBM's broader struggle to reclaim technological leadership .The study was conducted through a comprehensive review of IBM's market position, AI initiatives, leadership decisions, and real-world case studies of Watson in oncology. Key findings highlight IBM's inability to sustain innovation, AI adoption challenges, and difficulties in cloud computing competition. Despite investments in AI and restructuring efforts-including a 2020 corporate split-IBM continues to lag behind major tech rivals. This study underscores the importance of real-world data integration, transparent AI models, and strategic adaptability in ensuring AI success in healthcare and beyond. IBM's future depends on its ability to merge historical strengths with emerging technologies while navigating an increasingly competitive market.**

Keywords: AI Success Factors, Future of IBM, Technological Leadership, Emerging Technologies, Transparent AI Models, Real world data integration, Leadership Decision, Market position, AI adoption challenges.

I. Introduction

The integration of Artificial Intelligence (AI) in healthcare has revolutionized medical decision-making, offering the potential to enhance diagnostic accuracy, treatment personalization, and clinical efficiency. Among the pioneering AI-driven healthcare solutions, IBM Watson for Oncology was introduced as a groundbreaking cognitive computing system designed to assist oncologists in diagnosing and recommending treatment plans for cancer patients.

The promise of Watson for Oncology was to leverage AI and natural language processing (NLP) to analyze vast amounts of medical literature, clinical guidelines, and patient data to provide evidence-based treatment suggestions. Despite its ambitious goals, IBM Watson for Oncology faced significant challenges in real-world applications, raising concerns about the reliability, accuracy, and adaptability of AI-driven healthcare solutions. The failure to meet expectations not only impacted IBM's reputation in healthcare AI but also provided valuable lessons for the broader adoption of AI in medicine.

With healthcare AI continuing to evolve, it is crucial to analyze Watson's journey, identify the root causes of its shortcomings, and explore IBM's pivot beyond oncology into fields like genomics, clinical decision support, and drug discovery. Understanding these factors will shape the future of AI-driven healthcare innovations.



Fig 1.1 IBM Watson for Oncology Workflow

International Research Journal of Innovations in Engineering and Technology (IRJIET)
ISSN (online): 2581-3048
Volume 9, Special Issue INSPIRE'25, pp 116-120, April-2025
https://doi.org/10.47001/IRJIET/2025.INSPIRE19
International Conference on Sustainable Practices and Innovations in Research and Engineering (INSPIRE'25)

1.1 Problem Statement

While IBM Watson for Oncology was envisioned as a transformational tool in cancer treatment, it encountered critical challenges that hindered its effectiveness, including:

1. Inconsistencies in Treatment Recommendations: Reports highlighted discrepancies between Watson's suggestions and oncologists' expert opinions, raising concerns about reliability.
2. Limited Real-World Data Integration: The system struggled to process unstructured patient data effectively, making it difficult to personalize treatments.
3. Over reliance on Curated Data: Instead of learning dynamically from real-world patient cases, Watson primarily relied on pre-fed guidelines and medical literature.
4. Lack of Clinical Adoption: Oncologists found it difficult to integrate Watson into their workflows due to usability concerns and skepticism about its recommendations.
5. Market and Business Challenges: High implementation costs, limited return on investment (ROI), and difficulty scaling the technology led to IBM scaling back its Watson Health division.

These challenges raised fundamental questions about the feasibility of AI in complex medical decision-making, making it imperative to study where Watson for Oncology went wrong and how AI in healthcare can move forward effectively.

1.2 Objective of the Study

1. Analyze IBM Watson for Oncology's Vision & Implementation – Understanding how the system was designed, deployed, and expected to revolutionize oncology.
2. Identify Key Challenges & Reasons for Failure – Investigating the technical, clinical, and business obstacles that contributed to its underperformance.
3. Explore IBM's Strategic Shift Beyond Oncology – Examining how IBM redirected its AI healthcare initiatives toward genomics, clinical decision support, and drug discovery.
4. Extract Lessons for Future AI-Driven Healthcare Solutions – Providing insights into how AI applications in medicine can overcome Watson's limitations and achieve greater success.

By critically evaluating Watson for Oncology's trajectory, this study will offer valuable takeaways for AI-driven healthcare innovations, ensuring more robust, data-driven, and clinically relevant implementations in the future.

1.3 Scope of the Study

1. Technical Aspects of Watson for Oncology – How the AI system functioned, including data sources, algorithms, and learning models.
2. Challenges in Real-World Implementation – Barriers that limited Watson's effectiveness in clinical practice.
3. Case Studies & Market Response – Analyzing reported incidents of Watson's failures and stakeholder reactions.
4. IBM's Strategic Shift – How IBM moved beyond oncology into broader AI healthcare applications like genomics, clinical decision-making, and drug discovery.

Recommendations for improving AI-driven decision support tools to prevent similar pitfalls.

II. IBM Watson for Oncology – Development, Implementation, and Challenges

This chapter will provide a detailed analysis of IBM Watson for Oncology, focusing on its technological framework, real world implementation, key challenges, and eventual limitations. By understanding how Watson for Oncology was designed and deployed, we can assess the gaps that led to its struggles and IBM's subsequent shift beyond oncology.

2.1 Development of IBM Watson for Oncology

2.1.1 Vision and Objectives:

1. IBM aimed to revolutionize cancer treatment by using AI and cognitive computing to assist oncologists in decision making
2. Watson was designed to process vast medical literature, clinical trial data, and patient records to provide evidence based treatment recommendations.
3. The goal was to enhance treatment personalization and reduce variability in oncology decisions

2.1.2 Core AI Technologies Used:

1. Natural Language Processing (NLP) – Enabled Watson to interpret unstructured medical data (research papers, clinical notes).
2. Machine Learning Algorithms – Used to match patient cases with the most relevant treatment options.
3. Big Data Analytics – Analyzed vast datasets to generate evidence-based insights.
4. Integration with NCCN Guidelines – Ensured that Watson's recommendations were based on recognized oncology guidelines.

International Research Journal of Innovations in Engineering and Technology (IRJIET)
ISSN (online): 2581-3048
Volume 9, Special Issue INSPIRE'25, pp 116-120, April-2025
https://doi.org/10.47001/IRJIET/2025.INSPIRE19
International Conference on Sustainable Practices and Innovations in Research and Engineering (INSPIRE'25)

2.2 Implementation in Real-World Healthcare

2.2.1 Partnership with Hospitals and Research Centers:

1.IBM collaborated with leading hospitals like Memorial Sloan Kettering Cancer Center (MSKCC) to train Watson in oncology.

2.Deployment in countries like the U.S., India, Thailand, and South Korea aimed to improve cancer care globally.

2.2.2 Functionality in Clinical Workflows:

Oncologists would input patient case details, and Watson would generate prioritized treatment options with supporting evidence. Recommendations were based on a combination of NCCN guidelines, published literature, and clinical trial data.

2.3 Key Challenges and Limitations

2.3.1 Accuracy and Reliability Issues:

1. Several reports indicated that Watson recommended incorrect or unsafe treatments.
2. The system sometimes failed to align with expert oncologists' decisions, causing mistrust among medical professionals.

2.3.2 Data Limitations and Biases:

1. Watson relied heavily on curated data from MSKCC, limiting its ability to learn from real-world patient data.
2. It struggled with unstructured and incomplete patient records, reducing effectiveness.

2.3.3 Lack of Clinical Adoption:

1. Doctors found it difficult to integrate Watson into their workflows, citing usability issues.
2. Oncologists preferred their own expertise over AI generated recommendations, leading to resistance.

2.3.4 High Cost and Business Challenges:

1. Hospitals found Watson's implementation expensive, making widespread adoption difficult.
2. IBM faced low return on investment (ROI), eventually leading to a strategic shift away from Watson Health.

2.4 IBM's Shift Beyond Oncology

2.4.1 Expanding to Other Healthcare Domains:

1. IBM transitioned Watson's AI capabilities into genomics, drug discovery, and clinical decision support.
2. The goal was to enhance AI-driven medical innovations beyond cancer treatment.

2.4.2 Lessons Learned and Future AI Healthcare Applications:

1. Importance of Real-World Data – AI models must continuously learn from real patient cases, not just curated guidelines
2. Ensuring Clinical Validation – AI-generated recommendations should align with expert knowledge. Cost-Effective AI Deployment – Healthcare AI solutions must provide tangible financial and clinical benefits to hospitals.

2.4.3 Expected Benefits:

1. Faster Decision-Making – Reduced time spent on researching treatment options.
2. Personalized Treatment Plans – Matched patients with the most suitable therapies.
3. Evidence-Based Support – Ensured oncologists had data backed recommendations

III. Results & Solutions

3.1 Performance of IBM Watson for Oncology

IBM Watson for Oncology was designed to enhance cancer treatment decisions using AI-driven analysis. Its performance was evaluated based on various factors, including accuracy, speed, adaptability, and real-world implementation.

1. Efficient Data Processing: Watson quickly analyzed vast medical literature to suggest treatment plans.
2. Guideline-Based Recommendations: It followed standardized treatment protocols like NCCN guidelines.
3. Time-Saving for Physicians: Helped reduce research timenby providing evidence-based options.
4. Inconsistent in Complex Cases: Struggled with rare cancers and evolving treatment protocols.
5. Lack of Adaptability: Unable to fully integrate real-world physician experience and regional treatment variations.
6. Physician Distrust: Oncologists often disagreed with Watson's recommendations due to lack of clinical intuition.

3.2 Challenges Faced by IBM Watson for Oncology

1. Limited Real-World Adaptation – Watson relied primarily on structured data, failing to integrate physician intuition and evolving treatment protocols.

International Research Journal of Innovations in Engineering and Technology (IRJIET)
ISSN (online): 2581-3048
Volume 9, Special Issue INSPIRE'25, pp 116-120, April-2025
https://doi.org/10.47001/IRJIET/2025.INSPIRE19
International Conference on Sustainable Practices and Innovations in Research and Engineering (INSPIRE'25)

2. Physician Distrust & Resistance – Oncologists were skeptical about its accuracy, especially for complex and rare cancer cases.
3. High Implementation Costs – The expensive infrastructure and integration requirements made it difficult for hospitals to adopt Watson at scale.
4. Data Inconsistencies – Variations in patient data led to inconsistencies in Watson's recommendations.
5. Ethical & Legal Issues – AI-driven medical decisions raised concerns about liability and accountability in patient treatment.

Table 1: Traditional cancer treatment VS IBM Watson for oncology

CRITERIA	IBM WATSON FOR ONCOLOGY	TRADITIONAL ONCOLOGY DECISION-MAKING
Speed	Faster analysis	Slower due to manual research
Accuracy	Inconsistent in rare cases	Highly reliable in complex cases
Adaptability	Limited to its training data	Doctors adapt to realtime cases
Physician Acceptance	Moderate	High (Trusted expertise)

3.3 Solutions & Recommendations

Solution 1: Enhancing AI Learning & Real-Time Adaptation

1. Integrate physician feedback loops to allow AI to refine its recommendations.

2. Use real-world patient data and machine learning to improve decision-making.

3. Enable AI to adapt to evolving treatment protocols dynamically.

Solution 2: Improving Physician-AI Collaboration

1. Shift Watson's role from decision-maker to decision support system to gain oncologist trust.

2. Implement hybrid decision-making models, combining AI insights with human expertise. Offer extensive training programs for doctors to understand Watson's capabilities and limitations.

Solution 3: Reducing Costs & Enhancing Accessibility

1. Optimize AI models to run on cost-effective cloud-based systems.

2. Develop scalable pricing models to encourage adoption in mid-sized and smaller hospitals. Encourage government and private funding for AI-driven medical research.

Solution 4: Strengthening Data Quality & Ethical Considerations

1. Implement region-specific training datasets to improve Watson's adaptability.

2. Address data privacy and legal concerns by enhancing AI transparency.

3. Establish clear liability frameworks for AI-assisted medical decisions.

3.5 Future Prospects & Conclusion

Despite its setbacks, IBM Watson for Oncology has laid the foundation for AI-driven healthcare solutions. Future AI systems must focus on:

1. Personalized treatment recommendations based on patient history

2. Real-time learning models that evolve with medical advancements.

3. Stronger physician-AI collaboration to ensure clinical accuracy.



Figure 3.1: Human +AI collaboration

IV. Conclusion

The integration of IBM Watson for Oncology in the healthcare sector represents a transformative step toward AI-driven decision-making in medical treatments. This case study has explored the potential, challenges, and solutions associated with Watson's implementation. While the technology demonstrated promising results in processing vast amounts of medical data, its effectiveness was hindered by issues such as

International Research Journal of Innovations in Engineering and Technology (IRJIET)
ISSN (online): 2581-3048
Volume 9, Special Issue INSPIRE'25, pp 116-120, April-2025
https://doi.org/10.47001/IRJIET/2025.INSPIRE19
International Conference on Sustainable Practices and Innovations in Research and Engineering (INSPIRE'25)

data inconsistency, physician skepticism, and difficulty in adapting to real-world clinical complexities. However, by refining its algorithms, enhancing physician-AI collaboration, and integrating real-time patient feedback, Watson has the potential to revolutionize personalized medicine. The expected outcome of these improvements includes greater diagnostic accuracy, enhanced treatment recommendations, reduced physician workload, and increased accessibility to expert-level oncology care worldwide. With continuous advancements in AI and data driven healthcare, Watson can evolve into a more reliable and efficient tool that bridges the gap between medical expertise and technology. The future of AI-assisted healthcare depends on striking a balance between machine intelligence and human expertise, ensuring that technology serves as an enabler rather than a replacement. By addressing the current limitations and building trust among medical professionals, IBM Watson can set a benchmark for AI applications in medicine, ultimately leading to improved patient outcomes and a sustainable future for healthcare innovation

REFERENCES

[1] https://biomedikal.in/2017/10/ibm-watson-for-oncology/
[2] https://techgolly.com/ai-in-healthcare-ibm-watsonscontribution-to-cancer-research
[3] https://in.newsroom.ibm.com/2018-05-22-Apollo-Hospitals-Adopts-IBM-Watson-for-Oncology-and-IBM-Watson-for-Genomicsto-Help-Physicians-Make-Data-Driven-Cancer-Care-Decisions
[4] https://en.wikipedia.org/wiki/Merative?utm_source=chatgpt.com

AUTHORS BIOGRAPHY

Dr.S.Sathya, Associate Professor, Department of AI&DS, GRT Institute of Engineering and Technology, Tiruttani, Tamilnadu, India.

Pooja S,
UG Student, Department of AI&DS, GRT Institute of Engineering and Technology, Tiruttani, Tamilnadu, India.

Paruvathani G, UG Student, Department of AI&DS, GRT Institute of Engineering and Technology, Tiruttani, Tamilnadu, India.

Sharmi J, UG Student, Department of AI&DS, GRT Institute of Engineering and Technology, Tiruttani, Tamilnadu, India.

Citation of this Article:

Dr.S.Sathya, Pooja S, Paruvathani G, & Sharmi J. (2025). The Rise and Fall of IBM Watson in Healthcare: Lessons for Sustainable AI Innovations. In proceeding of International Conference on Sustainable Practices and Innovations in Research and Engineering (INSPIRE'25), published by *IRJIET*, Volume 9, Special Issue of INSPIRE'25, pp 116-120. Article DOI https://doi.org/10.47001/IRJIET/2025.INSPIRE19

****

